doi:10.1007/s12250-013-3390-x

Ackermann M, Padmanabhan R, 2001: De novo synthesis of RNA by the dengue virus RNA-dependent RNA polymerase exhibits temperature dependence at the initiation but not elongation phase[J]. J Biol Chem, 276, 39926-39937. doi: 10.1074/jbc.M104248200
Aleshin A, Shiryaev S, Strongin A, Liddington R, 2007: Structural evidence for regulation and specificity of flaviviral proteases and evolution of the Flaviviridae fold[J]. Protein Sci., 16, 795-806. doi: 10.1110/ps.072753207
Aravapalli S, Lai H, Teramoto T, Alliston K R, Lushington G H, Ferguson E L, Padmanabhan R, Groutas W C, 2012: Inhibitors of Dengue virus and West Nile virus proteases based on the aminobenzamide scaffold[J]. Bioorg Med Chem, 20, 4140-4148. doi: 10.1016/j.bmc.2012.04.055
Arias C F, Preugschat F, Strauss J H, 1993: Dengue 2 virus NS2B and NS3 form a stable complex that can cleave NS3 within the helicase domain[J]. Virology, 193, 888-899. doi: 10.1006/viro.1993.1198
Ashour J, Laurent-Rolle M, Shi P Y, Garcia-Sastre A, 2009: NS5 of dengue virus mediates STAT2 binding and degradation[J]. J Virol, 83, 5408-5418. doi: 10.1128/JVI.02188-08
Asnis D S, Conetta R, Waldman G, Teixeira A A, 2001: The West Nile virus encephalitis outbreak in the United States (1999-2000): from Flushing, New York, to beyond its borders[J]. Ann N Y Acad Sci, 951, 161-171.
Asnis D S, Conetta R, Teixeira A A, Waldman G, Sampson B A, 2000: The West Nile Virus outbreak of 1999 in New York: the Flushing Hospital experience[J]. Clin Infect Dis, 30, 413-418. doi: 10.1086/313737
Assenberg R, Mastrangelo E, Walter T S, Verma A, Milani M, Owens R J, Stuart D I, Grimes J M, Mancini E J, 2009: Crystal structure of a novel conformational state of the flavivirus NS3 protein: implications for polyprotein processing and viral replication[J]. J Virol, 83, 12895-12906. doi: 10.1128/JVI.00942-09
Bazan J F, Fletterick R J, 1989: Detection of a trypsin-like serine protease domain in flaviviruses and pestiviruses[J]. Virology, 171, 637-639. doi: 10.1016/0042-6822(89)90639-9
Best S M, Morris K L, Shannon J G, Robertson S J, Mitzel D N, Park G S, Boer E, Wolfinbarger J B, Bloom M E, 2005: Inhibition of interferon-stimulated JAK-STAT signaling by a tick-borne flavivirus and identification of NS5 as an interferon antagonist[J]. J. Virol., 79, 12828-12839. doi: 10.1128/JVI.79.20.12828-12839.2005
Bodenreider C, Beer D, Keller T H, Sonntag S, Wen D, Yap L, Yau Y H, Shochat S G, Huang D, Zhou T, Caflisch A, Su X C, Ozawa K, Otting G, Vasudevan S G, Lescar J, Lim S P, 2009: A fluorescence quenching assay to discriminate between specific and nonspecific inhibitors of dengue virus protease[J]. Anal Biochem, 395, 195-204. doi: 10.1016/j.ab.2009.08.013
Bressanelli S, Stiasny K, Allison S L, Stura E A, Duquerroy S, Lescar J, Heinz F X, Rey F A, 2004: Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation[J]. EMBO J., 23, 728-738. doi: 10.1038/sj.emboj.7600064
Brinton M A, 1981: Isolation of a replication-efficient mutant of West Nile virus from a persistently infected genetically resistant mouse cell culture[J]. J Virol, 39, 413-421.
Brinton M A, 2002: THE MOLECULAR BIOLOGY OF WEST NILE VIRUS: A New Invader of the Western Hemisphere[J]. Annu Rev Microbiol, 56, 371-402. doi: 10.1146/annurev.micro.56.012302.160654
Burke D S, Monath T P, 2001: Flaviviruses[J]. Lippincott William & Wilkins, , -.
CDC. 2010. CDC West Nile virus homepage. http://www.cdc.gov/ncidod/dvbid/westnile/surv&controlCaseCount03.htm.
Chambers T J, Grakoui A, Rice C M, 1991: Processing of the yellow fever virus nonstructural polyprotein: a catalytically active NS3 proteinase domain and NS2B are required for cleavages at dibasic sites[J]. J. Virol., 65, 6042-6050.
Chambers T J, Hahn C S, Galler R, Rice C M, 1990: Flavivirus genome organization, expression, and replication[J]. Annu Rev Microbiol, 44, 649-688. doi: 10.1146/annurev.mi.44.100190.003245
Chambers T J, Nestorowicz A, Amberg S M, Rice C M, 1993: Mutagenesis of the yellow fever virus NS2B protein: effects on proteolytic processing, NS2B-NS3 complex formation, and viral replication[J]. J Virol, 67, 6797-6807.
Chambers T J, Droll D A, Tang Y, Liang Y, Ganesh V K, Murthy K H, Nickells M, 2005: Yellow fever virus NS2B-NS3 protease: characterization of charged-to-alanine mutant and revertant viruses and analysis of polyprotein-cleavage activities[J]. J Gen Virol, 86, 1403-1413. doi: 10.1099/vir.0.80427-0
Chandramouli S, Joseph J S, Daudenarde S, Gatchalian J, Cornillez-Ty C, Kuhn P, 2010: Serotype-specific structural differences in the protease-cofactor complexes of the dengue virus family[J]. J Virol, 84, 3059-3067. doi: 10.1128/JVI.02044-09
Chanprapaph S, Saparpakorn P, Sangma C, Niyomrattanakit P, Hannongbua S, Angsuthanasombat C, Katzenmeier G, 2005: Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites[J]. Biochem Biophys Res Commun, 330, 1237-1246. doi: 10.1016/j.bbrc.2005.03.107
Chappell K J, Stoermer M J, Fairlie D P, Young P R, 2006: Insights to substrate binding and processing by West Nile Virus NS3 protease through combined modeling, protease mutagenesis, and kinetic studies[J]. J Biol Chem, 281, 38448-38458. doi: 10.1074/jbc.M607641200
Chappell K J, Stoermer M J, Fairlie D P, Young P R, 2008: West Nile Virus NS2B/NS3 protease as an antiviral target[J]. Curr Med Chem, 15, 2771-2784. doi: 10.2174/092986708786242804
Chappell K J, Stoermer M J, Fairlie D P, Young P R, 2008: Mutagenesis of the West Nile virus NS2B cofactor domain reveals two regions essential for protease activity[J]. J Gen Virol, 89, 1010-1014. doi: 10.1099/vir.0.83447-0
Cleaves G R, Dubin D T, 1979: Methylation status of intracellular dengue type 2 40 S RNA[J]. Virology, 96, 159-165. doi: 10.1016/0042-6822(79)90181-8
Cregar-Hernandez L, Jiao G S, Johnson A T, Lehrer A T, Wong T A, Margosiak S A, 2011: Small molecule pan-dengue and West Nile virus NS3 protease inhibitors[J]. Antivir Chem Chemother, 21, 209-217. doi: 10.3851/IMP1767
Daffis S, Szretter K J, Schriewer J, Li J, Youn S, Errett J, Lin T Y, Schneller S, Zust R, Dong H, Thiel V, Sen G C, Fensterl V, Klimstra W B, Pierson T C, Buller R M, Gale M, J r., Shi P Y, Diamond M S, 2010: 2'-O methylation of the viral mRNA cap evades host restriction by IFIT family members[J]. Nature, 468, 452-456. doi: 10.1038/nature09489
Deng J, Li N, Liu H, Zuo Z, Liew O W, Xu W, Chen G, Tong X, Tang W, Zhu J, Zuo J, Jiang H, Yang C G, Li J, Zhu W, 2012: Discovery of novel small molecule inhibitors of dengue viral NS2B-NS3 protease using virtual screening and scaffold hopping[J]. J Med Chem, 55, 6278-6293. doi: 10.1021/jm300146f
Dong H, Chang D C, Hua M H, Lim S P, Chionh Y H, Hia F, Lee Y H, Kukkaro P, Lok S M, Dedon P C, Shi P Y, 2012: 2'-O methylation of internal adenosine by flavivirus NS5 methyltransferase[J]. PLoS pathogens, 8, e1002642-. doi: 10.1371/journal.ppat.1002642
Egloff M P, Benarroch D, Selisko B, Romette J L, Canard B, 2002: An RNA cap (nucleoside-2'-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization[J]. Embo J, 21, 2757-2768. doi: 10.1093/emboj/21.11.2757
Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Otting G, Huang D, Caflisch A, 2009: Flaviviral protease inhibitors identified by fragment-based library docking into a structure generated by molecular dynamics[J]. J Med Chem, 52, 4860-4868. doi: 10.1021/jm900448m
Ekonomiuk D, Su X C, Ozawa K, Bodenreider C, Lim S P, Yin Z, Keller T H, Beer D, Patel V, Otting G, Caflisch A, Huang D, 2009: Discovery of a non-peptidic inhibitor of west nile virus NS3 protease by high-throughput docking[J]. PLoS Negl Trop Dis, 3, e356-. doi: 10.1371/journal.pntd.0000356
Erbel P, Schiering N, D'Arcy A, Renatus M, Kroemer M, Lim S, Yin Z, Keller T, Vasudevan S, Hommel U, 2006: Structural basis for the activation of flaviviral NS3 proteases from dengue and West Nile virus[J]. Nat. Struct. Mol. Biol., 13, 372-373. doi: 10.1038/nsmb1073
Ezgimen M, Lai H, Mueller N H, Lee K, Cuny G, Ostrov D A, Padmanabhan R, 2012: Characterization of the 8-hydroxyquinoline scaffold for inhibitors of West Nile virus serine protease[J]. Antiviral Res, 94, 18-24. doi: 10.1016/j.antiviral.2012.02.003
Falgout B, Miller R H, Lai C J, 1993: Deletion analysis of dengue virus type 4 nonstructural protein NS2B: identification of a domain required for NS2B-NS3 protease activity[J]. J Virol, 67, 2034-2042.
Falgout B, Bray M, Schlesinger J J, Lai C J, 1990: Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis[J]. J Virol, 64, 4356-4363.
Falgout B, Pethel M, Zhang Y M, Lai C J, 1991: Both nonstructural proteins NS2B and NS3 are required for the proteolytic processing of dengue virus nonstructural proteins[J]. J Virol, 65, 2467-2475.
Ganesh V K, Muller N, Judge K, Luan C H, Padmanabhan R, Murthy K H, 2005: Identification and characterization of nonsubstrate based inhibitors of the essential dengue and West Nile virus proteases[J]. Bioorg Med Chem, 13, 257-264. doi: 10.1016/j.bmc.2004.09.036
Gao Y, Cui T, Lam Y, 2010: Synthesis and disulfide bond connectivity-activity studies of a kalata B1-inspired cyclopeptide against dengue NS2B-NS3 protease[J]. Bioorg Med Chem, 18, 1331-1336. doi: 10.1016/j.bmc.2009.12.026
Gao Y, Samanta S, Cui T, Lam Y, 2013: Synthesis and in vitro Evaluation of West Nile Virus Protease Inhibitors Based on the 1, 3, 4, 5-Tetrasubstituted 1H-Pyrrol-2(5H)-one Scaffold[J]. ChemMedChem, 8, 1554-1560. doi: 10.1002/cmdc.201300244
Gouvea I E, Izidoro M A, Judice W A, Cezari M H, Caliendo G, Santagada V, dos Santos C N, Queiroz M H, Juliano M A, Young P R, Fairlie D P, Juliano L, 2007: Substrate specificity of recombinant dengue 2 virus NS2B-NS3 protease: influence of natural and unnatural basic amino acids on hydrolysis of synthetic fluorescent substrates[J]. Arch Biochem Biophys, 457, 187-196. doi: 10.1016/j.abb.2006.11.005
Grant D, Tan G K, Qing M, Ng J K, Yip A, Zou G, Xie X, Yuan Z, Schreiber M J, Schul W, Shi P Y, Alonso S, 2011: A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis[J]. J Virol, 85, 7775-7787. doi: 10.1128/JVI.00665-11
Guirakhoo F, Bolin R A, Roehrig J T, 1992: The Murray Valley encephalitis virus prM protein confers acid resistance to virus particles and alters the expression of epitopes within the R2 domain of E glycoprotein[J]. Virology, 191, 921-931. doi: 10.1016/0042-6822(92)90267-S
Guo J, Hayashi J, Seeger C, 2005: West nile virus inhibits the signal transduction pathway of alpha interferon[J]. J. Virol., 79, 1343-1350. doi: 10.1128/JVI.79.3.1343-1350.2005
Guyatt K J, Westaway E G, Khromykh A A, 2001: Expression and purification of enzymatically active recombinant RNA-dependent RNA polymerase (NS5) of the flavivirus Kunjin[J]. J Virol Methods, 92, 37-44. doi: 10.1016/S0166-0934(00)00270-6
Hammamy M Z, Haase C, Hammami M, Hilgenfeld R, Steinmetzer T, 2013: Development and characterization of new peptidomimetic inhibitors of the West Nile virus NS2B-NS3 protease[J]. ChemMedChem, 8, 231-241. doi: 10.1002/cmdc.201200497
Issur M, Geiss B J, Bougie I, Picard-Jean F, Despins S, Mayette J, Hobdey S E, Bisaillon M, 2009: The flavivirus NS5 protein is a true RNA guanylyltransferase that catalyzes a two-step reaction to form the RNA cap structure[J]. Rna, 15, 2340-2350. doi: 10.1261/rna.1609709
Jia F, Zou G, Fan J, Yuan Z, 2010: Identification of palmatine as an inhibitor of West Nile virus[J]. Arch Virol, 155, 1325-1329. doi: 10.1007/s00705-010-0702-4
Johnston P A, Phillips J, Shun T Y, Shinde S, Lazo J S, Huryn D M, Myers M C, Ratnikov B I, Smith J W, Su Y, Dahl R, Cosford N D, Shiryaev S A, Strongin A Y, 2007: HTS identifies novel and specific uncompetitive inhibitors of the two-component NS2B-NS3 proteinase of West Nile virus[J]. Assay Drug Dev Technol, 5, 737-750. doi: 10.1089/adt.2007.101
Kiat T S, Pippen R, Yusof R, Ibrahim H, Khalid N, Rahman N A, 2006: Inhibitory activity of cyclohexenyl chalcone derivatives and flavonoids of fingerroot, Boesenbergia rotunda (L.), towards dengue-2 virus NS3 protease[J]. Bioorg Med Chem Lett, 16, 3337-3340.
Knehans T, Schuller A, Doan D N, Nacro K, Hill J, Guntert P, Madhusudhan M S, Weil T, Vasudevan S G, 2011: Structure-guided fragment-based in silico drug design of dengue protease inhibitors[J]. J Comput Aided Mol Des, 25, 263-274. doi: 10.1007/s10822-011-9418-0
Knox J E, Ma N L, Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, Keller T H, 2006: Peptide inhibitors of West Nile NS3 protease: SAR study of tetrapeptide aldehyde inhibitors[J]. J Med Chem, 49, 6585-6590. doi: 10.1021/jm0607606
Koonin E V, 1993: Computer-assisted identification of a putative methyltransferase domain in NS5 protein of flaviviruses and lambda 2 protein of reovirus[J]. J Gen Virol, 74, 733-740. doi: 10.1099/0022-1317-74-4-733
Kramer L D, Bernard K A, 2001: West Nile virus infection in birds and mammals[J]. Ann N Y Acad Sci, 951, 84-93.
Kramer L D, Li J, Shi P Y, 2007: West Nile virus[J]. Lancet Neurol, 6, 171-181. doi: 10.1016/S1474-4422(07)70030-3
Kummerer B M, Rice C M, 2002: Mutations in the yellow fever virus nonstructural protein NS2A selectively block production of infectious particles[J]. J. Virol., 76, 4773-4784. doi: 10.1128/JVI.76.10.4773-4784.2002
Lai H, Sridhar Prasad G, Padmanabhan R, 2013: Characterization of 8-hydroxyquinoline derivatives containing aminobenzothiazole as inhibitors of dengue virus type 2 protease in vitro[J]. Antiviral Res, 97, 74-80. doi: 10.1016/j.antiviral.2012.10.009
Lai H, Dou D, Aravapalli S, Teramoto T, Lushington G H, Mwania T M, Alliston K R, Eichhorn D M, Padmanabhan R, Groutas W C, 2013: Design, synthesis and characterization of novel 1, 2-benzisothiazol-3(2H)-one and 1, 3, 4-oxadiazole hybrid derivatives: potent inhibitors of Dengue and West Nile virus NS2B/NS3 proteases[J]. Bioorg Med Chem, 21, 102-113. doi: 10.1016/j.bmc.2012.10.058
Leung D, Schroder K, White H, Fang N-X, Stoermer M, Abbenante G, Martin J, PR Y, Fairlie D, 2001: Activity of recombinant dengue 2 virus NS3 protease in the presence of a truncated NS2B co-factor, small peptide substrates, and inhibitors[J]. J. Biol. Chem., 276, 45762-45771. doi: 10.1074/jbc.M107360200
Leung J Y, Pijlman G P, Kondratieva N, Hyde J, Mackenzie J M, Khromykh A A, 2008: Role of nonstructural protein NS2A in flavivirus assembly[J]. J Virol, 82, 4731-4741. doi: 10.1128/JVI.00002-08
Li H, Clum S, You S, Ebner K E, Padmanabhan R, 1999: The serine protease and RNA-stimulated nucleoside triphosphatase and RNA helicase functional domains of dengue virus type 2 NS3 converge within a region of 20 amino acids[J]. J Virol, 73, 3108-3116.
Li J, Lim S P, Beer D, Patel V, Wen D, Tumanut C, Tully D C, Williams J A, Jiricek J, Priestle J P, Harris J L, Vasudevan S G, 2005: Functional profiling of recombinant NS3 proteases from all four serotypes of dengue virus using tetrapeptide and octapeptide substrate libraries[J]. J Biol Chem, 280, 28766-28774. doi: 10.1074/jbc.M500588200
Li L, Lok S M, Yu I M, Zhang Y, Kuhn R J, Chen J, Rossmann M G, 2008: The flavivirus precursor membrane-envelope protein complex: structure and maturation[J]. Science, 319, 1830-1834. doi: 10.1126/science.1153263
Lin C, Kwong A D, Perni R B, 2006: Discovery and development of VX-950, a novel, covalent, and reversible inhibitor of hepatitis C virus NS3[J]. 4A serine protease. Infect Disord Drug Targets, 6, 3-16.
Lin K, Perni R B, Kwong A D, Lin C, 2006: VX-950, a novel hepatitis C virus (HCV) NS3-4A protease inhibitor, exhibits potent antiviral activities in HCv replicon cells[J]. Antimicrob Agents Chemother, 50, 1813-1822. doi: 10.1128/AAC.50.5.1813-1822.2006
Lindenbach B D, Rice C M, 1997: trans-Complementation of yellow fever virus NS1 reveals a role in early RNA replication[J]. J. Virol., 71, 9608-9617.
Lindenbach B D, Rice C M, 1999: Genetic interaction of flavivirus nonstructural proteins NS1 and NS4A as a determinant of replicase function[J]. J Virol, 73, 4611-4621.
Lindenbach B D, Thiel H J, Rice C M, 2007: Flaviviridae: The Virus and Their Replication, Fourth ed[J]. Lippincott William & Wilkins, , -.
Luo D, Xu T, Hunke C, Gruber G, Vasudevan S G, Lescar J, 2008: Crystalstructure of the NS3 protease-helicase from dengue virus[J]. J Virol, 82, 173-183. doi: 10.1128/JVI.01788-07
Luo D, Wei N, Doan D N, Paradkar P N, Chong Y, Davidson A D, Kotaka M, Lescar J, Vasudevan S G, 2010: Flexibility between the protease and helicase domains of the dengue virus NS3 protein conferred by the linker region and its functional implications[J]. J Biol Chem, 285, 18817-18827. doi: 10.1074/jbc.M109.090936
Luo D, Xu T, Watson R P, Scherer-Becker D, Sampath A, Jahnke W, Yeong S S, Wang C H, Lim S P, Strongin A, Vasudevan S G, Lescar J, 2008: Insights into RNA unwinding and ATP hydrolysis by the flavivirus NS3 protein[J]. Embo J, 27, 3209-3219. doi: 10.1038/emboj.2008.232
Mangano D T, Tudor I C, Dietzel C, 2006: The risk associated with aprotinin in cardiac surgery[J]. N Engl J Med, 354, 353-365. doi: 10.1056/NEJMoa051379
Mangano D T, Miao Y, Vuylsteke A, Tudor I C, Juneja R, Filipescu D, Hoeft A, Fontes M L, Hillel Z, Ott E, Titov T, Dietzel C, Levin J, 2007: Mortality associated with aprotinin during 5 years following coronary artery bypass graft surgery[J]. JAMA, 297, 471-479. doi: 10.1001/jama.297.5.471
Marianneau P, Steffan A M, Royer C, Drouet M T, Jaeck D, Kirn A, Deubel V, 1999: Infection of primary cultures of human Kupffer cells by Dengue virus: no viral progeny synthesis, but cytokine production is evident[J]. J Virol, 73, 5201-5206.
Menendez-Arias L, 2010: Molecular basis of human immunodeficiency virus drug resistance: an update[J]. Antiviral Res, 85, 210-231. doi: 10.1016/j.antiviral.2009.07.006
Miller S, Kastner S, Krijnse-Locker J, Buhler S, Bartenschlager R, 2007: The non-structural protein 4A of dengue virus is an integral membrane protein inducing membrane alterations in a 2K-regulated manner[J]. J Biol Chem, 282, 8873-8882. doi: 10.1074/jbc.M609919200
Modis Y, Ogata S, Clements D, Harrison S C, 2004: Structure of the dengue virus envelope protein after membrane fusion[J]. Nature, 427, 313-319. doi: 10.1038/nature02165
Mueller N H, Yon C, Ganesh V K, Padmanabhan R, 2007: Characterization of the West Nile virus protease substrate specificity and inhibitors[J]. Int J Biochem Cell Biol, 39, 606-614. doi: 10.1016/j.biocel.2006.10.025
Mueller N H, Pattabiraman N, Ansarah-Sobrinho C, Viswanathan P, Pierson T C, Padmanabhan R, 2008: Identification and biochemical characterization of small-molecule inhibitors of west nile virus serine protease by a high-throughput screen[J]. Antimicrob Agents Chemother, 52, 3385-3393. doi: 10.1128/AAC.01508-07
Munoz-Jordan J L, Sanchez-Burgos G G, Laurent-Rolle M, Garcia-Sastre A, 2003: Inhibition of interferon signaling by dengue virus[J]. Proc. Natl. Acad. Sci. USA, 100, 14333-14338. doi: 10.1073/pnas.2335168100
Munoz-Jordan J L, Laurent-Rolle M, Ashour J, Martinez-Sobrido L, Ashok M, Lipkin W I, Garcia-Sastre A, 2005: Inhibition of Alpha/Beta Interferon Signaling by the NS4B Protein of Flaviviruses[J]. J. Virol., 79, 8004-8013. doi: 10.1128/JVI.79.13.8004-8013.2005
Muylaert I R, Galler R, Rice C M, 1997: Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation[J]. J. Virol., 71, 291-298.
Nall T A, Chappell K J, Stoermer M J, Fang N X, Tyndall J D, Young P R, Fairlie D P, 2004: Enzymatic characterization and homology model of a catalytically active recombinant West Nile virus NS3 protease[J]. J Biol Chem, 279, 48535-48542. doi: 10.1074/jbc.M406810200
Nitsche C, Steuer C, Klein C D, 2011: Arylcyanoacrylamides as inhibitors of the Dengue and West Nile virus proteases[J]. Bioorg Med Chem, 19, 7318-7337. doi: 10.1016/j.bmc.2011.10.061
Nitsche C, Behnam M A, Steuer C, Klein C D, 2012: Retro peptide-hybrids as selective inhibitors of the Dengue virus NS2B-NS3 protease[J]. Antiviral Res, 94, 72-79. doi: 10.1016/j.antiviral.2012.02.008
Niyomrattanakit P, Winoyanuwattikun P, Chanprapaph S, Angsuthanasombat C, Panyim S, Katzenmeier G, 2004: Identification of residues in the dengue virus type 2 NS2B cofactor that are critical for NS3 protease activation[J]. J Virol, 78, 13708-13716. doi: 10.1128/JVI.78.24.13708-13716.2004
Noble C G, Seh C C, Chao A T, Shi P Y, 2012: Ligand-bound structures of the dengue virus protease reveal the active conformation[J]. Journal of Virology, 86, 438-446. doi: 10.1128/JVI.06225-11
Noble C G, Chen Y L, Dong H, Gu F, Lim S P, Schul W, Wang Q Y, Shi P Y, 2010: Strategies for development of Dengue virus inhibitors[J]. Antiviral Res, 85, 450-462. doi: 10.1016/j.antiviral.2009.12.011
Pambudi S, Kawashita N, Phanthanawiboon S, Omokoko M D, Masrinoul P, Yamashita A, Limkittikul K, Yasunaga T, Takagi T, Ikuta K, and Kurosu T. 2013. A Small Compound Targeting the Interaction between Nonstructural Proteins 2B and 3 Inhibits Dengue Virus Replication. Biochem Biophys Res Commun: in press (doi: 10.1016/j.bbrc.2013.1009.1078).
Phong W Y, Moreland N J, Lim S P, Wen D, Paradkar P N, Vasudevan S G, 2011: Dengue protease activity: the structural integrity and interaction of NS2B with NS3 protease and its potential as a drug target[J]. Bioscience reports, , -.
Radichev I, Shiryaev S A, Aleshin A E, Ratnikov B I, Smith J W, Liddington R C, Strongin A Y, 2008: Structure-based mutagenesis identifies important novel determinants of the NS2B cofactor of the West Nile virus two-component NS2B-NS3 proteinase[J]. J Gen Virol, 89, 636-641. doi: 10.1099/vir.0.83359-0
Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, Dong H, Deas T, Zhou Y, Li H, Shi P, 2006: West nile virus 5'-cap structure is formed by sequential guanine N-7 and ribose 2'-O methylations by nonstructural protein 5[J]. J. Virol., 80, 8362-8370. doi: 10.1128/JVI.00814-06
Rice C M, Lenches E M, Eddy S R, Shin S J, Sheets R L, Strauss J H, 1985: Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution[J]. Science, 229, 726-733. doi: 10.1126/science.4023707
Robin G, Chappell K, Stoermer M J, Hu S H, Young P R, Fairlie D P, Martin J L, 2009: Structure of West Nile virus NS3 protease: ligand stabilization of the catalytic conformation[J]. J Mol Biol, 385, 1568-1577. doi: 10.1016/j.jmb.2008.11.026
Romano K P, Ali A, Royer W E, Schiffer C A, 2010: Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding[J]. Proc Natl Acad Sci U S A, 107, 20986-20991. doi: 10.1073/pnas.1006370107
Roosendaal J, Westaway E G, Khromykh A, Mackenzie J M, 2006: Regulated cleavages at the West Nile virus NS4A-2K-NS4B junctions play a major role in rearranging cytoplasmic membranes and Golgi trafficking of the NS4A protein[J]. J Virol, 80, 4623-4632. doi: 10.1128/JVI.80.9.4623-4632.2006
Rothan H A, Han H C, Ramasamy T S, Othman S, Rahman N A, Yusof R, 2012: Inhibition of dengue NS2B-NS3 protease and viral replication in Vero cells by recombinant retrocyclin-1[J]. BMC Infect Dis, 12, 314-. doi: 10.1186/1471-2334-12-314
Samanta S, Cui T, Lam Y, 2012: Discovery, synthesis, and in vitro evaluation of West Nile virus protease inhibitors based on the 9, 10-dihydro-3H, 4aH-1, 3, 9, 10a-tetraazaphenanthren-4-one scaffold[J]. ChemMedChem, 7, 1210-1216. doi: 10.1002/cmdc.v7.7
Sarrazin C, Rouzier R, Wagner F, Forestier N, Larrey D, Gupta S K, Hussain M, Shah A, Cutler D, Zhang J, Zeuzem S, 2007: SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders[J]. Gastroenterology, 132, 1270-1278. doi: 10.1053/j.gastro.2007.01.041
Schuller A, Yin Z, Brian Chia C S, Doan D N, Kim H K, Shang L, Loh T P, Hill J, Vasudevan S G, 2011: Tripeptide inhibitors of dengue and West Nile virus NS2B-NS3 protease[J]. Antiviral Res, 92, 96-101. doi: 10.1016/j.antiviral.2011.07.002
Shi P Y, Tilgner M, Lo M K, 2002: Construction and characterization of subgenomic replicons of New York strain of West Nile virus[J]. Virology, 296, 219-233. doi: 10.1006/viro.2002.1453
Shi P Y, Tilgner M, Lo M K, Kent K A, Bernard K A, 2002: Infectious cDNA clone of the epidemic west nile virus from New York City[J]. J Virol, 76, 5847-5856. doi: 10.1128/JVI.76.12.5847-5856.2002
Shi P Y, Kauffman E B, Ren P, Felton A, Tai J H, Dupuis A P, 2nd, Jones S A, Ngo K A, Nicholas D C, Maffei J, Ebel G D, Bernard K A, and Kramer L D. 2001. High-throughput detection of West Nile virus RNA. J Clin Microbiol, 39: 1264-1271.
Shiryaev S, Ratnikov B, Chekanov A, Sikora S, Rozanov D, Godzik A, Wang J, Smith J, Huang Z, Lindberg I, Samuel M, Diamond M, Strongin A, 2006: Cleavage targets and the D-arginine-based inhibitors of the West Nile virus NS3 processing proteinase[J]. Biochem J., 393, 503-511. doi: 10.1042/BJ20051374
Sidique S, Shiryaev S A, Ratnikov B I, Herath A, Su Y, Strongin A Y, Cosford N D, 2009: Structure-activity relationship and improved hydrolytic stability of pyrazole derivatives that are allosteric inhibitors of West Nile Virus NS2B-NS3 proteinase[J]. Bioorg Med Chem Lett, 19, 5773-5777. doi: 10.1016/j.bmcl.2009.07.150
Steuer C, Gege C, Fischl W, Heinonen K H, Bartenschlager R, Klein C D, 2011: Synthesis and biological evaluation of alpha-ketoamides as inhibitors of the Dengue virus protease with antiviral activity in cell-culture[J]. Bioorg Med Chem, 19, 4067-4074. doi: 10.1016/j.bmc.2011.05.015
Stoermer M J, Chappell K J, Liebscher S, Jensen C M, Gan C H, Gupta P K, Xu W J, Young P R, Fairlie D P, 2008: Potent cationic inhibitors of West Nile virus NS2B/NS3 protease with serum stability, cell permeability and antiviral activity[J]. J Med Chem, 51, 5714-5721. doi: 10.1021/jm800503y
Tan B H, Fu J, Sugrue R J, Yap E H, Chan Y C, Tan Y H, 1996: Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity[J]. Virology, 216, 317-325. doi: 10.1006/viro.1996.0067
Tassaneetrithep B, Burgess T H, Granelli-Piperno A, Trumpfheller C, Finke J, Sun W, Eller M A, Pattanapanyasat K, Sarasombath S, Birx D L, Steinman R M, Schlesinger S, Marovich M A, 2003: DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells[J]. J Exp Med, 197, 823-829. doi: 10.1084/jem.20021840
Tiew K C, Dou D, Teramoto T, Lai H, Alliston K R, Lushington G H, Padmanabhan R, Groutas W C, 2012: Inhibition of Dengue virus and West Nile virus proteases by click chemistry-derived benz[d]isothiazol-3(2H)-one derivatives[J]. Bioorg Med Chem, 20, 1213-1221. doi: 10.1016/j.bmc.2011.12.047
Tomlinson S M, Watowich S J, 2011: Anthracene-based inhibitors of dengue virus NS2B-NS3 protease[J]. Antiviral Res, 89, 127-135. doi: 10.1016/j.antiviral.2010.12.006
Tomlinson S M, Watowich S J, 2012: Use of parallel validation high-throughput screens to reduce false positives and identify novel dengue NS2B-NS3 protease inhibitors[J]. Antiviral Res, 93, 245-252. doi: 10.1016/j.antiviral.2011.12.003
Tomlinson S M, Malmstrom R D, Russo A, Mueller N, Pang Y P, Watowich S J, 2009: Structure-based discovery of dengue virus protease inhibitors[J]. Antiviral Res, 82, 110-114. doi: 10.1016/j.antiviral.2009.02.190
Umareddy I, Chao A, Sampath A, Gu F, Vasudevan S G, 2006: Dengue virus NS4B interacts with NS3 and dissociates it from single-stranded RNA[J]. J Gen Virol, 87, 2605-2614. doi: 10.1099/vir.0.81844-0
USGS. 2010. Disease Maps 2010. http://diseasemaps.usgs.gov/.
Warrener P, Tamura J K, Collett M S, 1993: RNA-stimulated NTPase activity associated with yellow fever virus NS3 protein expressed in bacteria[J]. J Virol, 67, 989-996.
Wegzyn C M, Wyles D L, 2012: Antiviral drug advances in the treatment of human immunodeficiency virus (HIV) and chronic hepatitis C virus (HCV)[J]. Curr Opin Pharmacol, 12, 556-561. doi: 10.1016/j.coph.2012.06.005
Wengler G, 1981: Terminal sequences of the genome and replicative-from RNA of the flavivirus West Nile virus: absence of poly(A) and possible role in RNA replication[J]. Virology, 113, 544-555. doi: 10.1016/0042-6822(81)90182-3
Wengler G, 1991: The carboxy-terminal part of the NS 3 protein of the West Nile flavivirus can be isolated as a soluble protein after proteolytic cleavage and represents an RNA-stimulated NTPase[J]. Virology, 184, 707-715. doi: 10.1016/0042-6822(91)90440-M
Westaway E G, Brinton M A, Gaidamovich S Y, Horzinek M C, Igarashi A, Kaariainen L, Lvov D K, Porterfield J S, Russell P K, Trent D W, 1985: Flaviviridae[J]. Intervirol., 24, 183-192. doi: 10.1159/000149642
WHO. 2009. Immunization, vaccines and biologicals: Japanese encephalitis. <http://www.who.int/nuvi/je/en/>>.
WHO. 2009. Dengue factsheet. <http://www.who.int/mediacentre/factsheets/fs117/en/>.
WHO. 2009. Yellow fever factsheet. <http://www.who.int/mediacentre/factsheets/fs100/en/>.
Wyles D L, 2012: Beyond telaprevir and boceprevir: resistance and new agents for hepatitis C virus infection[J]. Top Antivir Med, 20, 139-145.
Wyles D L, 2013: Antiviral resistance and the future landscape of hepatitis C virus infection therapy[J]. J Infect Dis, 207, S33-39.
Xu S, Li H, Shao X, Fan C, Ericksen B, Liu J, Chi C, Wang C, 2012: Critical effect of peptide cyclization on the potency of peptide inhibitors against Dengue virus NS2B-NS3 protease[J]. J Med Chem, 55, 6881-6887. doi: 10.1021/jm300655h
Yang C C, Hsieh Y C, Lee S J, Wu S H, Liao C L, Tsao C H, Chao Y S, Chern J H, Wu C P, Yueh A, 2011: Novel dengue virus-specific NS2B/NS3 protease inhibitor, BP2109, discovered by a high-throughput screening assay[J]. Antimicrob Agents Chemother, 55, 229-238. doi: 10.1128/AAC.00855-10
Yin Z, Patel S J, Wang W L, Wang G, Chan W L, Rao K R, Alam J, Jeyaraj D A, Ngew X, Patel V, Beer D, Lim S P, Vasudevan S G, Keller T H, 2006: Peptide inhibitors of Dengue virus NS3 protease[J]. Part 1: Warhead. Bioorg Med Chem Lett, 16, 36-39. doi: 10.1016/j.bmcl.2005.09.062
Yin Z, Patel S J, Wang W L, Chan W L, Ranga Rao K R, Wang G, Ngew X, Patel V, Beer D, Knox J E, Ma N L, Ehrhardt C, Lim S P, Vasudevan S G, Keller T H, 2006: Peptide inhibitors of dengue virus NS3 protease[J]. Part 2: SAR study of tetrapeptide aldehyde inhibitors. Bioorg Med Chem Lett, 16, 40-43.
Zhang Y, Corver J, Chipman P R, Zhang W, Pletnev S V, Sedlak D, Baker T S, Strauss J H, Kuhn R J, Rossmann M G, 2003: Structures of immature flavivirus particles[J]. EMBO J., 22, 2604-2613. doi: 10.1093/emboj/cdg270
Zhou Y, Ray D, Zhao Y, Dong H, Ren S, Li Z, Guo Y, Bernard K A, Shi P Y, Li H, 2007: Structure and function of flavivirus NS5 methyltransferase[J]. J Virol, 81, 3891-3903. doi: 10.1128/JVI.02704-06